Recent clinical trials of immunotherapy in non-small-cell lung cancer

被引：7
|
作者：
Gkolfinopoulos, Stavros [1 ]
Mountzios, Giannis [2 ]
机构：
[1] BOC Oncol Ctr, Med Oncol Dept, CY-2006 Nicosia, Cyprus
[2] Henry Dunant Hosp Ctr, Med Oncol Dept 2, Athens 11526, Greece
来源：
IMMUNOTHERAPY | 2019年 / 11卷 / 06期
关键词：
atezolizumab; avelumab; checkpoint inhibitors; durvalumab; ipilimumab; nivolumab; non-small-cell lung cancer; pembrolizumab; DOCETAXEL; NIVOLUMAB; INTERLEUKIN-2; ATEZOLIZUMAB; BURDEN;
D O I：
10.2217/imt-2019-0021
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：461 / 466
页数：6
相关论文
共 50 条
  • [31] Advances in Immunotherapy and Implications for Current Practice in Non-Small-Cell Lung Cancer
    Steuer, Conor E.
    Ramalingam, Suresh S.
    JCO ONCOLOGY PRACTICE, 2021, 17 (11) : 662 - +
  • [32] Safety evaluation of durvalumab for the treatment of non-small-cell lung cancer
    Shibata, Yuji
    Murakami, Shuji
    EXPERT OPINION ON DRUG SAFETY, 2020, 19 (06) : 653 - 659
  • [33] Immunotherapy in Patients with Advanced Non-Small Cell Lung Cancer Lacking Driver Mutations and Future Perspectives
    De Mello, Ramon Andrade Bezerra
    Voscaboinik, Rafael
    Luciano, Joao Vittor Pires
    Cremonese, Rafaela Vilela
    Amaral, Giovanna Araujo
    Castelo-Branco, Pedro
    Antoniou, Georgios
    CANCERS, 2022, 14 (01)
  • [34] Impact of Smoking History on Response to Immunotherapy in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
    Zhao, Wenhua
    Jiang, Wei
    Wang, Huilin
    He, Jianbo
    Su, Cuiyun
    Yu, Qitao
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [35] Delta radiomics model for the prediction of progression-free survival time in advanced non-small-cell lung cancer patients after immunotherapy
    Xie, Dong
    Xu, Fangyi
    Zhu, Wenchao
    Pu, Cailing
    Huang, Shaoyu
    Lou, Kaihua
    Wu, Yan
    Huang, Dingpin
    He, Cong
    Hu, Hongjie
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [36] A Review of Immunotherapy in Non-Small-Cell Lung Cancer
    Capella, Mariana Pilon
    Pang, Steph A.
    Magalhaes, Marcos A.
    Esfahani, Khashayar
    CURRENT ONCOLOGY, 2024, 31 (06) : 3495 - 3512
  • [37] Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab
    Facchinetti, Francesco
    Veneziani, Michele
    Buti, Sebastiano
    Gelsomino, Francesco
    Squadrilli, Anna
    Bordi, Paola
    Bersanelli, Melissa
    Cosenza, Agnese
    Ferri, Leonarda
    Rapacchi, Elena
    Mazzaschi, Giulia
    Leonardi, Francesco
    Quaini, Federico
    Ardizzoni, Andrea
    Missale, Gabriele
    Tiseo, Marcello
    IMMUNOTHERAPY, 2018, 10 (08) : 681 - 694
  • [38] Toxicity with small molecule and immunotherapy combinations in non-small cell lung cancer
    Adderley, H.
    Blackhall, F. H.
    Lindsay, C. R.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (03) : 589 - 595
  • [39] The efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer with liver metastases
    Kitadai, Rui
    Okuma, Yusuke
    Hakozaki, Taiki
    Hosomi, Yukio
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2020, 146 (03) : 777 - 785
  • [40] Sequential therapy with ramucirumab and/or checkpoint inhibitors for non-small-cell lung cancer in routine practice
    Molife, Cliff
    Hess, Lisa M.
    Cui, Zhanglin Lin
    Li, Xiaohong Ivy
    Beyrer, Julie
    Mahoui, Malika
    Oton, Ana B.
    FUTURE ONCOLOGY, 2019, 15 (25) : 2915 - 2931
12345